SABCS 2021 | Samuraciclib in combination with fulvestrant in patients with advanced HR+/HER2- breast cancer

Charles Coombes, MD, PhD, Imperial College London, London, UK, discusses samuraciclib, a first-in-class, oral, selective inhibitor of CDK7, which was evaluated in combination with fulvestrant in patients with advanced hormone receptor-positive HER2-negative breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.